Ravasio, R., H. Cranmer, I. Kearns, R. Viti, and S. Corinti. “Cost-Utility Analysis of Brigatinib Compared to Alectinib in the Treatment of ALK-Positive NSCLC in Patients Previously Not Treated With an ALK Inhibitor”. AboutOpen, vol. 9, no. 1, Oct. 2022, pp. 92-104, doi:10.33393/ao.2022.2450.